Delayed activation of extracellular-signal-regulated kinase 1/2 is involved in genistein- and equol-induced cell proliferation and estrogen-receptor-α-mediated transcription in MCF-7 breast cancer cells

Journal of Nutritional Biochemistry

Volumn 21, Issue 5, 2010, Pages 390-396

  Liu, Huaqing ^a,b   Du, Juan ^a   Hu, Chunyan ^a   Qi, Hong ^a   Wang, Xinru ^a   Wang, Shoulin ^a   Liu, Qizhan ^a   Li, Zhong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b BENGBU MEDICAL COLLEGE   (China)

Author keywords

Equol; ER transactivation; ERK1 2 signaling pathway; Genistein; MCF 7 breast cancer cells

Indexed keywords

4 HYDROXYTAMOXIFEN; EQUOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GENISTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN PS2; UO 126;

ARTICLE; BREAST CARCINOGENESIS; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ESTROGEN RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENES, REPORTER; GENISTEIN; HUMANS; ISOFLAVONES; PHOSPHORYLATION; PHYTOESTROGENS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 77951498821     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2009.01.016     Document Type: Article

References (45)

1. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003, 3:768-780.
2. Adlercreutz H., Mousavi Y., Clark J., Höckerstedt K., Hämäläinen E., Wähälä K., et al. Dietary phytoestrogens and cancer: in vitro and in vivo studies. J Steroid Biochem Mol Biol 1992, 41:331-337.
3. Miksicek R.J. Estrogenic flavonoids: structural requirements for biological activity. Proc Soc Exp Biol Med 1995, 208(1):44-50.
4. Rowland I., Faughnan M., Hoey L., Wähälä K., Williamson G., Cassidy A. Bioavailability of phyto-oestrogens. Br J Nutr 2003, 89:S45-S58.
5. Wang T.T., Sathymoorthy N., Phang J.M. Molecular effects genistein on estrogen receptor mediated pathways. Carcinogenesis 1996, 17:271-275.
6. Santell R.C., Chang Y.C., Nair M.G., Helferich W.G. Dietary genistein exerts estrogenic effects on the uterus, mammary gland, and hypothalamic/pituitary axis in rats. J Nutr 1997, 127:263-269.
7. Allred C.D., Allred K.F., Ju Y.H., Clausen L.M., Doerge D.R., Schantz S.L., et al. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats. Carcinogenesis 2004, 25:211-218.
8. Ju Y.H., Doerge D.R., Allred K.F., Allred C.D., Helferich W.G. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002, 62:2474-2477.
9. Setchell K.D., Brown N.M., Lydeking-Olsen E. The clinical importance of the metabolite equol - a clue to the effectiveness of soy and its isoflavones. J Nutr 2002, 132:3577-3584.
10. Chang Y.C., Nair M.G. Metabolism of daidzein and genistein by intestinal bacteria. J Nat Prod 1995, 58:1892-1896.
11. Morito K., Hirose T., Kinjo J., Hirakawa T., Okawa M., Nohara T., et al. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull 2001, 24:351-356.
12. Feigelson H.S., Henderson B.E. Estrogens and breast cancer. Carcinogenesis 1996, 17:2279-2284.
13. McDonnell D.P., Norris J.D. Connections and regulation of the human estrogen receptor. Science 2002, 296:1642-1644.
14. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139:4252-4263.
15. Katzenellenbogen B.S. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol Reprod 1996, 54:287-293.
16. Kelly M.J., Levin E.R. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 2001, 12:152-156.
17. Razandi M., Pedram A., Merchenthaler I., Greene G.L., Levin E.R. Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol 2004, 18(12):2854-2865.
18. Santen R.J., Song R.X., McPherson R., Kumar R., Adam L., Jeng M.H., et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002, 80:239-256.
19. Chong H., Vikis H.G., Guan K. Mechanisms of regulating the raf kinase family. Cell Signal 2003, 15:463-469.
20. Takeyoshi M., Yamasaki K., Sawaki M., Nakai M., Noda S., Takatsuki M. The efficacy of endocrine disruptor screening tests in detecting anti-estrogenic effects downstream of receptor-ligand interactions. Toxicol Lett 2002, 126(2):91-98.
21. Tschugguel W., Dietrich W., Zhegu Z., Stonek F., Kolbus A., Huber J.C. Differential regulation of proteasome-dependent estrogen receptor alpha and beta turnover in cultured human uterine artery endothelial cells. J Clin Endocrinol Metab 2003, 88(5):2281-2287.
22. Fotsis T., Pepper M., Adlercreutz H., Fleischmann G., Hase T., Montesano R., et al. Genistein, a dietary-derived inhibitor of in vivo angiogenesis. Proc Natl Acad Sci USA 1993, 90:2690-2694.
23. Foster J.S., Wimalasena J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 1996, 10:488-498.
24. Prall O.W., Rogan E.M., Musgrove E.A., Watts C.K., Sutherland R.L. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 1998, 18:4499-4508.
25. Li Z., Liu W., Mo B., Hu C., Liu H., Qi H., et al. Caffeine overcomes genistein-induced G2/M cell cycle arrest in breast cancer cells. Nutr Cancer 2008, 60(3):382-388.
26. Li Z., Li J., Mo B., Hu C., Liu H., Qi H., et al. Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. Cell Biol Toxicol 2008, 24(5):401-409.
27. Lobenhofer E.K., Hupper G., Iglehadrt J.D., Marks J.R. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen- induced mitogenesis. Cell Growth Differ 2000, 11:99-110.
28. Jones S., Kazlauskas A. Growth-factor-dependent mitogenesis requires two distinct phases of signaling. Nat Cell Biol 2001, 3:165-172.
29. Karin M., Hunter T. Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Curr Biol 1995, 5:747-757.
30. Prud'homme J.F., Jolivet A., Pichon M.F., Savouret J.F., Milgrom E. Monoclonal antibodies against native ant denatured forms of estrogen-induced breast cancer protein (BCEI/pS2) obtained by expression in Escherichia coli. Cancer Res 1990, 50(8):2390-2396.
31. Zava D.T., Blen M., Duwe G. Estrogenic activity of natural and synthetic estrogens in human breast cancer cells in culture. Environ Health Perspect 1997, 105:637-645.
32. Sathyamoorthy N., Wang T.T. Differential effects of dietary phyto-oestrogens daidzein and equol on human breast cancer MCF-7 cells. Eur J Cancer 1997, 33:2384-2389.
33. Zivadinovic D., Watson C.S. Membrane estrogen receptor-alpha levels predict estrogen- induced ERK1/2 activation in MCF-7 cells. Breast Cancer Res 2005, 7:R130-R144.
34. Pedram A., Razandi M., Levin E.R. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 2006, 20:1996-2009.
35. Fernando R., Wimalasena J. Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: ras-dependent nongenomic pathways requiring signalling through ERK and Akt. Mol Biol Cell 2004, 15:3266-3284.
36. Filardo E., Quinn J., Frackelton A.R., Bland K. Estrogen action via the G-protein- coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002, 16:70-84.
37. Song R., McPherson R., Adam L., Bao Y., Shupnik M., Kumar R., et al. Linkage of rapid estrogen action to MAPK activation by ERα-Sch association and Shc pathway activation. Mol Endocrinol 2002, 16:116-127.
38. Caristi S., Galera J.L., Matarese F., Imai M., Caporali S., Cancemi M., et al. Estrogens do not modify MAP kinase-dependent nuclear signaling during stimulation of early G(1) progression in human breast cancer cells. Cancer Res 2001, 61:6360-6366.
39. Sun H., Charles C.H., Lau L.F., Tonks N.K. MKP-1(3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 1993, 75:487-493.
40. Lin Y., Chuang S., Yang J. ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway. J Biol Chem 2003, 278:21534-21541.
41. Dos Santos E.G., Dieudonne M.N., Pecquery R., Le Moal V., Giudicelli Y., Lacasa D. Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes. Endocrinology 2002, 143:930-940.
42. Woo C.H., Lim J.H., Kim J.H. VCAM-1 upregulation via PKCα-p38 kinase-linked cascade mediates the TNF-α-induced leukocyte adhesion and emigration in the lung airway epithelium. Am J Physiol Lung Cell Mol Physiol 2005, 288:L307-L316.
43. Barchiesi F., Jackson E.K., Imthurn B., Fingerle J., Gillespie D.G., Dubey R.K. Differential regulation of estrogen receptor subtypes alpha and beta in human aortic smooth muscle cells by oligonucleotides and estradiol. J Clin Endocrinol Metab 2004, 89(5):2373-2381.
44. Dowsett M., Ashworth A. New biology of the oestrogen receptor. Lancet 2003, 362:260-262.
45. Reid G., Hübner M.R., Metivier R., Brand H., Denger S., Manu D., et al. Cyclic, proteasome mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003, 11:695-707.